This site is intended for UK healthcare professionals only

NEWS

 

Keep up to date with the latest news on bladder health, management and treatment.

Have you got a story to share? Email the team today.

AstraZeneca have withdrawn Imfinzi (durvalumab) indication for metastatic bladder cancer
1 August 2021
AstraZeneca withdraws Imfinzi indication in US for advanced bladder cancer

AstraZeneca has announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer. The decision was made in consultation with the Food and Drug Administration (FDA).

In May 2017, Imfinzi was granted accelerated approval in the US based on promising tumour response rates and duration of response data from Study 1108, a Phase I/II trial that evaluated the safety and efficacy of Imfinzi in advanced solid tumours, including previously treated bladder cancer. Continued approval was contingent on results from the DANUBE Phase III trial in the 1st-line metastatic bladder cancer setting, which did not meet its primary endpoints in 2020.

The withdrawal is aligned with FDA guidance for evaluating indications with accelerated approvals that did not meet post-marketing requirements, as part of a broader industry-wide evaluation. This withdrawal does not impact the indication outside the US and does not impact other approved Imfinzi indications within or outside the US.

Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: “The science of immunotherapy has moved swiftly over the past few years, bringing new options to patients at an unprecedented pace. While the withdrawal in previously treated metastatic bladder cancer is disappointing, we respect the principles FDA set out when the accelerated approval pathway was founded and remain committed to bringing new and innovative options to patients. In the last three years, Imfinzi has become an important standard of care in multiple lung cancer settings, an area of considerable focus for AstraZeneca.”

Visit the Bladder Interest Group news page to explore recent industry updates.

Latest News

Luja™ shows significant improvement in bladder emptying

Study results show that Coloplast’s new intermittent male catheter with 80+ micro-holes, Luja, achieved complete bladder emptying in one free flow* in 90% of catheterisations. Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male...

Artificial Intelligence used in bladder cancer treatment assessment

A computerised artificial intelligence (AI)-based decision support system (CDSS-T) enhanced the performance of clinicians when assessing patients’ response to chemotherapy prior to radical cystectomy, according to results from a small multi-institutional observer...

New treatment for urothelial cancer approved by NICE

Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment for urothelial cancer – avelumab – following its recommendation for routine NHS funding in final draft guidance published NICE. The recommendation for this...